In this month's installment of Ask the PI, ONCOLOGY spoke with Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
Oncology Vol 32 No 12
In this side of the Point/Counterpoint, Drs. Bernard and Flaig state that genomic testing should be routine in the management of prostate cancer patients.
In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.
Advertisement
Advertisement
Trending on CancerNetwork
1
KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma
2
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
3
Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma
4
ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma
5
